SiC Fab Bet: Archean’s High-Voltage Upside for Shareholders

Archean Chemical leads India in bromine and industrial salt exports, powering pharma, agrochem and textiles with steady cash from long-term deals. These core ops deliver reliable revenue despite monsoon hiccups, forming a solid base for shareholders seeking stability amid commodity swings. ​ The game-changer: Archean is building India's first commercial silicon carbide (SiC) fab in Odisha via subsidiary SiCSem, targeting 60,000 wafers and 96 million packaged units yearly. Partnering with UK-based Clas-SiC gives exclusive tech access for power devices in EVs, railways, defense, data centers and renewables. Groundbreaking hit Nov 1, 2025; full ops in 30 months with Rs 2,067 crore capex, 60-65% govt-backed. ​ Global SiC market eyes 26% CAGR to $14B+ by 2030, fueled by efficient power chips for green tech. Archean taps this via bromine-linked zinc-bromide batteries too, diversifying beyond salts. ​ H1 FY26 revenue rose 10% to Rs 523 crore (79% exports), but EBITDA flat at Rs 172 crore, margins down 390bps to 32.8% from prolonged rains. PBT dipped 9%, yet balance sheet stays strong. ​ For shareholders, upsides dominate: Core cash funds SiC without debt overload, govt subsidies cut risks, and SiC success could lift margins/returns (current RoCE 12.8%, RoE 9.8%) vs peers. P/E at 37x premiums 3-yr median but reflects growth optionality in India's chip boom. ​ Downsides loom: Fabs need huge capex, tech mastery and 2-3yr ramps; delays erode value. Weather/volatility hits near-term earnings, testing patience. ​ Net positive—Archean's pivot builds enduring value, blending cash cow stability with high-growth SiC tailwinds. Beneficial for long-haul holders eyeing re-rating over pure chemical plays.